By: Marcus J. Hopkins, Blogger
On Thursday, December 8th, the Community Access National Network (CANN) hosted a community roundtable on Hepatitis C (HCV) and Aging at the Pharmaceutical Research and Manufacturers of America® (PhRMA) headquarters in Washington, D.C. The event featured four presenters – Ambrose Delpino (PharmD, practicing HIV pharmacist [AAHIVP], Senior Manager, Virology, Walgreens), Fabian Ancar (a patient who successfully achieved a Sustained Virologic Response [SVR] while co-infected with HIV and HCV), Marissa Tonelli (Senior Manager of Capacity Building, HealthHIV, and Senior Manager of HealthHCV), and Chris Taylor (Senior Director, Hepatitis, National Alliance of State and Territorial AIDS Directors).
Of the four presenters, Dr. Delpino presented the most statistically pertinent presentation (as the others spoke primarily about their experiences, research, and how their organizations engage in advocacy on the local, state, and Federal levels), and the statistics that we’ll be reporting, here, are from his slides. Some of the issues raised during this panel will be further explored in further posts, so this entry will serve as a summation of his main points.
On the basics of infection, Dr. Delpino’s presentation reported that 2.7–3.9 million Americans are estimated to be infected with HCV, with an estimated 17,000 new infections annually. Both he and HEAL Blog note that this estimation is likely very low, as HCV screening, disease monitoring, tracking, and reporting are notoriously problematic, as capturing certain populations (e.g. – Rural, People Who Inject Drugs (PWIDs), et cetera) is difficult at best. It is also estimated that one in thirty Baby Boomers (people born between 1945-1965) are infected with HCV – five times greater incidence than other adults. The estimated cost to the healthcare system, including HCV-symptom-related hospitalizations and treatments is estimated to be over $80 billion over the next ten years.
The primary reason why Baby Boomers (the “birth cohort”) are so much more likely to be infected is related to the facts that HCV is a relatively new discovery in terms of diseases, blood supplies were not adequately screened for HCV prior to 1992, and universal precautions related to sanitation were not, prior to the discovery of HIV, necessarily the standard of care (SOC). This means that anyone who received a blood transfusion or any other blood product prior to 1992 is at risk of having contracted HCV; this also means that anyone who received transplanted organs or had improperly sterilized equipment used on them prior to universal precautions being in place is also at risk.
Outside of the birth cohort, it is estimated that 60% of all HCV infections are believed to be related to injection drug use (IDU). For every 100 people infected with HCV, 75-85% will develop a chronic infection, 60-70% will develop liver disease, 5-20% will develop liver cirrhosis, and 1-5% will die as a result of their infection. What makes this frustrating for HCV advocates is that the cost per SVR in a single 12-week round of the most popular treatment (Harvoni – $94,500) is far less expensive in the short term than the long-term costs associated with chronic HCV infection.
In future posts, we will be examining the pipeline process that it often takes for patients infected with HCV to receive medications to treat their disease, one of the most compelling slides in Dr. Delpino’s presentation. We will also be sharing some of the personal testimony of the patient, Fabian Ancar, whose story was presented at the panel.
Disclaimer: HEAL Blogs do not necessarily reflect the views of the Community Access National Network (CANN), but rather they provide a neutral platform whereby the author serves to promote open, honest discussion about Hepatitis-related issues and updates. Please note that the content of some of the HEAL Blogs might be graphic due to the nature of the issues being addressed in it.